The CANVAS study (ClinicalTrials.gov, numbers, NCT01032629 and NCT01989754) confirmed that SGLT2 inhibitors could indeed significantly reduce the incidence of HF (hazard ratio: 0.67; 95% confidential interval: 0.52–0.87) (1). The gene discussed is SLC5A2; the disease is hydrops fetalis.